Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals (LON:HEMO) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

Do analysts rate HEMO or ORPH?

Given Open Orphan's higher probable upside, analysts plainly believe Open Orphan is more favorable than Hemogenyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemogenyx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Open Orphan	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has higher valuation and earnings, HEMO or ORPH?

Open Orphan has higher revenue and earnings than Hemogenyx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£5.18M	-£0.01	-129.90
Open Orphan	£34.71M	0.00	N/A	N/A	N/A

Do institutionals & insiders hold more shares of HEMO or ORPH?

0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer HEMO or ORPH?

Hemogenyx Pharmaceuticals received 55 more outperform votes than Open Orphan when rated by MarketBeat users. Likewise, 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote while only 0.00% of users gave Open Orphan an outperform vote.

Company	Underperform	Outperform
Hemogenyx Pharmaceuticals	Outperform Votes 55 57.89%	Underperform Votes 40 42.11%
Open Orphan	Outperform Votes No Votes	Underperform Votes 2 100.00%

Does the media prefer HEMO or ORPH?

In the previous week, Open Orphan had 3 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 3 mentions for Open Orphan and 0 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.75 beat Open Orphan's score of -0.04 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Positive
Open Orphan	Neutral

Is HEMO or ORPH more profitable?

Open Orphan's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-155.97%	-37.79%
Open Orphan	N/A	N/A	N/A

Summary

Open Orphan beats Hemogenyx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.